Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic NK-like cells GAIA-102

A preparation of allogeneic, off-the-shelf (OTS), ex-vivo activated and expanded natural killer (NK)-like cells, with a CD3-negative/CD56bright/CD57-negative immature phenotype, with potential cytolytic and antineoplastic activities. Upon infusion, allogeneic NK-like cells GAIA-102 may lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate anti-tumor immune responses.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	GAIA 102 GAIA-102 GAIA102

allogeneic NK-like cells GAIA-102

Search NCI's Drug Dictionary